GlassScriptPhysician profile
John M Cahill
NPI 1124071337
$3,553.39
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $173 · 2021: $163 · 2022: $588 · 2023: $579 · 2024: $717 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $764.21 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $512.12 | 2022-2025 | |
| Pfizer INC. | $305.28 | 2019-2025 | |
| Amgen INC. | $294.85 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.79 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $230.72 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $214.37 | 2022-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.31 | 2019-2025 | Lifevest |
| Abbott Laboratories | $172.37 | 2020-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $131.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $79.64 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $71.70 | 2024 | Ozempic, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $50.79 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $48.46 | 2021-2023 | |
| Chiesi USA, INC. | $46.70 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $38.88 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $35.97 | 2023-2025 | Verquvo |
| Cvrx, INC. | $28.68 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $16.74 | 2024 | |
| Veryan Medical Incorporated | $14.65 | 2024 | Biomimics 3d Vascular Stent System |
| Medtronic, INC. | $13.88 | 2024 | Venaseal |
| Bard Peripheral Vascular, INC. | $12.85 | 2023 | Lutonix Drug Coated Balloon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cahill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.